Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
Medical Affairs is a function within the biopharmaceutical, consumer healthcare, and MedTech industries that sits alongside other functions including Research & Development (R&D) and Commercial as one of the strategic pillars of the industry. R&D develops new drugs, devices and diagnostics; Commercial markets and sells these products; and Medical Affairs generates and communicates data that help healthcare professionals (HCPs), payors, policy makers and others make informed decisions that ensure the best use of treatments to benefit patients. In this way, Medical Affairs plays a vital role in providing scientific evidence and understanding to appropriately change clinical practice.
Just as there are many roles within R&D and Commercial, individuals working within Medical Affairs are responsible for many activities, especially including the following:
At the MAPS 2022 Global Annual Meeting, MAPS sits down to chat with José Borbolla, Global Executive Medical Director at Esai, and Augusto Grinspan, VP Medical Affairs and Head LATAM with Merck KGaA about developments in the practice and direction of Medical Affairs in Latin America. Augusto and José are also co-chairs of the MAPS Latin America Chapter.
This webinar will analyze the current state of Medical Affairs in Japan, highlight progress made and provide suggestions on what we can do together to make Medical Affairs in Japan even more effective.
This webinar will be covering:
1. MA in Japan today: progress and highlights
a. Leadership requirements in Japan to bring MA to the next level
b. MA has become more strategic across all companies
c. What are the competencies required to succeed?
2. Looking into the future of MA in Japan
a. How to engage more with Patients/Patient Advocacy groups
b. How to bring more value to customers, scientific leaders and health systems
c. How to better engage academia and health authority group through scientific exchange
3. Opportunities for improving effectiveness
a. Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
MAPS speaks with Tim Mikhelashvili, PharmD, CEO & Co-Founder, Amedea Pharma, Inc. and Riaz Abbas, Learning and Performance Lead, JAPAC Medical, Amgen about innovative approaches to Medical Affairs External Education.
As Medical Affairs professionals, it's easy to focus on the tasks that are right in front of us everyday. In this interview with Monica de Abadal, SVP and Head of Medical Affairs, North America we sat down at the MAPS 2022 Global Annual Meeting to take a step back. Here is how Medical Affairs benefits patients and society. Watch the full interview here.
This podcast, recorded at the MAPS 2022 Global Annual Meeting, addresses the unique position of Medical Affairs in the rare disease space & how our work in this area is essential for patient benefit.
Medical technologies such as medical devices and diagnostics are set apart from pharmaceuticals in that successful deployment depends on not only equipping health care providers with the theoretical knowledge of best and safest use but also ensuring users’ practical competence. Simply, with medical technologies across the spectrum from noninvasive diagnostics to high-risk therapeutics, clinical outcomes and patient safety depend on both proper education and proper training. In fact, this training is often a gatekeeper for use, as governments, trade organizations, and even hospitals may require medical staff to be adequately trained before new medical devices can be used in their settings. External education and training of health care professionals is largely the responsibility of External Education teams within Medical Affairs. This article details the importance of the External Education function and describes best practices for the implementation of External Education related to medical diagnostics/devices within a manufacturer’s organization.
Medical Affairs describes itself as a third strategic pillar in the biopharmaceutical and MedTech industries alongside R&D and Commercial. But is this truly the case or is Medical Affairs' strategic role still aspirational? And if it is in some ways aspirational, what does Medical Affairs need to do in order to truly achieve its position alongside R&D and Commercial? Here, three Medical Affairs leaders discuss these questions and offer their perspective for the future of the function.
In this white paper we will discuss various insights that should inform the creation and refinement of the iMC Strategy and Plan (iMC S/P), in addition to the traditional inputs that Medical Communications teams commonly use. The objectives are to (1) explain value of an insights-driven collaborative approach to creating an iMC S/P, (2) elucidate best practices for collecting and synthesizing integrated insights that are relevant to Medical Communications, and (3) operationalizing an insights-driven approach to create and update an iMC S/P.
MAPS is excited to announce the appointment of Tamas Koncz, MD, MSc, PhD, Chief Medical Officer for the Inflammation and Immunology Business at Pfizer, to the MAPS Board of Directors.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.